Literature DB >> 15994742

Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma.

A Caroline Heijckmann1, Maya S P Huijberts, Piet Geusens, Jolanda de Vries, Paul P C A Menheere, Bruce H R Wolffenbuttel.   

Abstract

OBJECTIVE: Untreated hyperthyroidism and treatment with high doses of thyroid hormone are associated with osteoporosis. However, their effect on bone turnover, their contribution to bone mineral density (BMD) in the context of other clinical risk factors for osteoporosis and the prevalence of vertebral fractures is not well documented.
DESIGN: Cross-sectional study.
METHODS: We studied 59 patients receiving L-thyroxine suppressive therapy for differentiated thyroid carcinoma (DTC). BMD of the hip was measured by dual X-ray absorptiometry (DXA) and lateral DXA pictures of the lumbar and thoracic vertebrae were performed. Bone resorption was measured by C-telopeptides of type I collagen (ICTP) and bone formation by procollagen type I N-propeptide (PINP). Clinical risk factors for osteoporosis were evaluated using a questionnaire.
RESULTS: Z-scores of BMD were similar as the NHANES (National Health and Nutrition Examination Survey) III reference group in women and men, also after long-term (> 10 years) suppression therapy. Patients in the lowest and highest quartile of BMD showed significant differences in the presence of clinical risk factors. ICTP levels were significantly higher than in age-matched controls, PINP levels were not different. We found four patients with a prevalent vertebral fracture.
CONCLUSIONS: We conclude that patients with well-differentiated thyroid carcinoma are not at increased risk of developing low bone mass nor have a higher prevalence of vertebral fracture at least when treated with relatively low doses of L-thyroxine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994742     DOI: 10.1530/eje.1.01933

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  18 in total

Review 1.  Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk Patients.

Authors:  E N Klein Hesselink; T P Links
Journal:  Eur Thyroid J       Date:  2015-06-11

Review 2.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

3.  Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma.

Authors:  Jordi L Reverter; Eulàlia Colomé; Susana Holgado; Eva Aguilera; Berta Soldevila; Lourdes Mateo; Anna Sanmartí
Journal:  Endocrine       Date:  2010-04-16       Impact factor: 3.633

Review 4.  Skeletal health in patients with differentiated thyroid carcinoma.

Authors:  M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti
Journal:  J Endocrinol Invest       Date:  2020-07-21       Impact factor: 4.256

5.  Bone demineralization in postmenopausal women: role of anamnestic risk factors.

Authors:  Sandro La Vignera; Rosita A Condorelli; Enzo Vicari; Chiara Nicoletti; Aldo E Calogero
Journal:  Int J Endocrinol       Date:  2012-07-26       Impact factor: 3.257

6.  Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men.

Authors:  El Hadidy M El Hadidy; Mohamed Ghonaim; Soma Sh Abd El Gawad; Mohamed Abou El Atta
Journal:  BMC Endocr Disord       Date:  2011-08-06       Impact factor: 2.763

7.  Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma.

Authors:  Thaís Gomes de Melo; Lígia Vera Montalli da Assumpção; Allan de Oliveira Santos; Denise Engelbrecht Zantut-Wittmann
Journal:  Thyroid Res       Date:  2015-06-02

8.  Multi-targeted approach in the treatment of thyroid cancer.

Authors:  Scott N Pinchot; Rebecca S Sippel; Herbert Chen
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

9.  Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study.

Authors:  A C Heijckmann; M Drent; B Dumitrescu; J De Vries; A C Nieuwenhuijzen Kruseman; B H R Wolffenbuttel; P Geusens; M S P Huijberts
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

10.  Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma.

Authors:  Chei Won Kim; Seokbo Hong; Se Hwan Oh; Jung Jin Lee; Joo Young Han; Seongbin Hong; So Hun Kim; Moonsuk Nam; Yong Seong Kim
Journal:  J Bone Metab       Date:  2015-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.